Mylan Calls Allergan Restasis Patent Deal A 'Desperate Tactic'
Executive Summary
Allergan's potential Restasis generic rival wasted no time attacking the company in court documents over the controversial deal Allergan signed with a Native American tribe to thwart generic competition.
You may also be interested in...
Allergan's Tribe Deal Over Restasis Sparks Ire From Legislators
Pharmaceutical manufacturers have been hoping to fly under Washington, D.C.'s radar, but Allergan's attempt to shield Restasis from the IPR process using a controversial deal with a Native American tribe, has led to calls for an investigation.
Allergan's Tribe Deal Over Restasis Sparks Ire From Legislators
Pharmaceutical manufacturers have been hoping to fly under Washington, D.C.'s radar, but Allergan's attempt to shield Restasis from the IPR process using a controversial deal with a Native American tribe, has led to calls for an investigation.
Too Bold By Half: Allergan’s Latest Moves And Pharma’s Leadership Deficit
Allergan proudly describes itself as a 'bold' company, and its latest move to protect its Restasis franchise certainly qualifies as a reason why. But Allergan’s unlikely position as the industry’s self-appointed leader in social responsibility should make the rest of the industry cringe.